玻璃体内注射雷珠单抗治疗新生血管性年龄相关性黄斑变性的疗效及对患者血清CRP VEGF 眼压和视力的影响

doi:10.3969/j.issn.1006-6233.2020.09.017

摘要
图/表
参考文献
相关文章 (10)

全文: PDF (1273 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 探究玻璃体内注射雷珠单抗治疗新生血管性年龄相关性黄斑变性(nAMD)的疗效及对患者血清C反应蛋白(CRP)、血管内皮生长因子(VEGF)、眼压和视力的影响。方法: 选取我院74例nAMD患者为研究对象,采用随机数字表法通过简单随机分组分为雷珠单抗组及康柏西普组,各37例,两组均经玻璃体内注射治疗。比较两组治疗前、治疗4周、治疗12周时视力[最佳矫正视力(BCVA)]、黄斑中心凹视网膜厚度(CRT)、眼压及血清CRP、VEGF水平差异,以治疗12周时脉络膜新生血管(CNV)渗漏情况评估临床疗效,并记录治疗期间并发症发生情况。结果: 两组治疗前后眼压组间及组内比较,差异均无统计学意义(P>0.05);两组组内治疗前后视力、CRT及血清CRP、VEGF比较,均为治疗前>治疗4周>治疗12周(P<0.05);雷珠单抗组治疗4周、12周时CRT及血清CRP、VEGF低于康柏西普组(P<0.05),两组治疗4周、12周时视力比较,差异均无统计学意义(P>0.05)。两组临床疗效和治疗期间并发症发生情况比较,差异均无统计学意义(P>0.05)。结论: 在玻璃体内注射治疗nAMD时,康柏西普疗效及安全性可与雷珠单抗相当,但雷珠单抗在改善CRT、降低CRP和VEGF表达方面具有显著优势,临床应用价值高。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	韩嵩

关键词 ：年龄相关性黄斑变性, 新生血管性, 雷珠单抗, 康柏西普, 渗漏

Abstract：Objective: To investigate the efficacy of intravitreal injection of Ranibizumab in the treatment of neovascular age-related macular degeneration (nAMD) and its effects on serum C-reactive protein (CRP), vascular endothelial growth factor (VEGF), intraocular pressure and visual acuity of patients.Methods: Seventy-four patients with nAMD in our hospital were selected as the research subjects, and they were categorized as the Ranibizumab group and the Conbercept group with random number table method, with 37 cases in each group.The two groups were treated by intravitreal injection.The visual acuity [best corrected visual acuity (BCVA)], central retinal thickness (CRT), intraocular pressure and levels of serum CRP and VEGF before treatment and 4 weeks and 12 weeks after treatment and choroidal neovascularization (CNV) leakage at 12 weeks after treatment were compared between the two groups, and the clinical efficacy was evaluated, and the occurrence of complications were recorded during treatment.Results: There was no significant difference in intraocular pressure before and after treatment between the groups and within the groups (P>0.05).Comparison of visual acuity, CRT, serum CRP and VEGF before and after treatment in the two groups all showed before treatment> at 4 weeks after treatment>at 12 weeks after treatment (P<0.05).The CRT, serum CRP and VEGF in Ranibizumab group 4 and 12 weeks after treatment were lower than those in Conbercept group (P<0.05).There was no significant difference in visual acuity between the two groups 4 and 12 weeks after treatment (P>0.05).There were no significant differences in clinical efficacy and occurrence of complications during treatment between the two groups (P>0.05).Conclusion: In the case of intravitreal injection for nAMD, the efficacy and safety of Conbercept are comparable to those of Ranibizumab, but Ranibizumab has significant advantages in improving CRT and reducing expressions of CRP and VEGF, and it has high clinical application value.

Key words： Age-related macular degeneration Neovascular Ranibizumab Conbercept Leakage

基金资助:辽宁省卫生厅科研基金项目,(编号:2014F325840)

引用本文:

韩嵩. 玻璃体内注射雷珠单抗治疗新生血管性年龄相关性黄斑变性的疗效及对患者血清CRP VEGF 眼压和视力的影响[J]. 河北医学, 2020, 26(9): 1478-1482.
HAN Song. Efficacy of Intravitreal Injection of Ranibizumab on Neovascular Age-Related Macular Degeneration and Its Effects on Serum CRP VEGF Intraocular Pressure and Visual Acuity. HeBei Med, 2020, 26(9): 1478-1482.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2020.09.017 或 http://www.hbyxzzs.cn/CN/Y2020/V26/I9/1478

[1] McGuinness MB,Finger RP,Karahalios A,et al.Age-related macular degeneration and mortality: the melbourne collaborative cohort Study[J].Eye,2017,31(9):1345~1357.
[2] Zhao R,Camino A,Wang J,et al.Automated drusen detection in dry age-related macular degeneration by multiple-depth, en face optical coherence tomography[J].Biomedical Optics Express,2017,8(11):5049~5064.
[3] 丁小燕,王志容,孙立梅.创造向未来:湿性AMD治疗进展及展望[J].中华实验眼科杂志,2019,37(1):63~68.
[4] 中华医学会眼科学分会眼底病学组.中国老年性黄斑变性临床诊断治疗路径[J].中华眼底病杂志,2013,29(4):343~355.
[5] 高欢欢,杜之渝,晏丕松,等.近视眼患者波前像差和对比敏感度相关分析[J].中华眼科杂志,2018,54(10):748~755.
[6] 杨玉青,安致稳,杨秀荣,等.益气养阴散结通络法联合针刺治疗湿性年龄相关性黄斑变性疗效探析[J].河北中医药学报,2019,34(2):23~25,47.
[7] 文小娟,蒋鹏飞,彭俊,等.蛴螬提取物对脉络膜新生血管中趋化因子受体3及其配体嗜酸性粒细胞趋化因子表达的影响[J].湖南中医药大学学报,2019,39(11):1326~1330.
[8] 朱祥祥,陈震,饶卓群,等.年龄相关性黄斑变性患者血浆miR-146a和miR-155水平检测及临床意义[J].临床眼科杂志,2019,27(3):231~234.
[9] 王爽,段素芳,牛秉轩,等.康柏西普对实验性脉络膜新生血管的作用机制研究[J].眼科新进展,2019,39(9):829~832.
[10] Tadayoni R,Waldstein SM,Boscia F,et al.Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion[J].Ophthalmology,2017,124(12):1778~1787.
[11] Minami Y,Nagaoka T,Ishibazawa A,et al.Short-term effects of intravitreal ranibizumab therapy on diabetic macular edema[J].Bmc Ophthalmology,2017,17(1):28~33.
[12] 俞林笔,宋小莉,邢雁飞,等.雷珠单抗注射液联合复方血栓通胶囊对年龄相关性黄斑变性患者临床疗效研究[J].河北医学,2019,25(5):800~804.